Nuformix Plc (GB:NFX)
LSE:NFX
Want to see GB:NFX full AI Analyst Report?
NFX Stock Chart & Stats
0.23 p
<0.01 p(2.11%)
At close: 4:00 PM EST
0.23 p
<0.01 p(2.11%)
Day’s Range― - ―
52-Week Range0.07 p - 0.56 p
Previous CloseN/A
Volume1.00M
Average Volume (3M)97.88M
Market Cap
£4.83M
Enterprise Value3.39M
Total Cash (Recent Filing)£930.28K
Total Debt (Recent Filing)£0.00
Price to Earnings (P/E)―
Beta-0.06
Next Earnings
Feb 03, 2027EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)<0.01
Shares Outstanding2,609,750,000
10 Day Avg. Volume69,476,590
30 Day Avg. Volume97,880,797
Financial Highlights & Ratios
PEG Ratio0.06
Price to Book (P/B)5.17
Price to Sales (P/S)0.00
P/FCF Ratio-6.35
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Low Leverage / Debt-free Balance SheetA sustained zero-debt position reduces financial risk and preserves strategic optionality. For a cash-burning biotech, lack of leverage lowers fixed obligations, making future capital raises less urgent and giving management flexibility to prioritize R&D or licensing without debt service pressure.
Proprietary Cocrystal Technology PlatformOwning a platform that reformulates APIs into improved solid-state forms is a durable strategic asset. Platform IP and technical expertise in stability and bioavailability create differentiated capabilities, enabling licensing, partnerships, or targeted product development in fibrotic indications.
Evidence Of Cost Control (smaller 2025 Loss)A materially smaller 2025 loss indicates management has tightened costs or removed one-offs. Sustainable expense discipline can stretch runway and lower reliance on frequent financing, improving the company's ability to advance development milestones with limited resources.
Bears Say
No Meaningful RevenueThree consecutive years of zero revenue show the company has not yet commercialized products, leaving long-term viability dependent on R&D success, licensing deals, or future approvals. Absent revenue, sustainable operations hinge on external funding or transformational partnerships.
Consistent Negative Cash Flow / Cash BurnPersistent negative operating and free cash flow forces reliance on capital raises, which can dilute shareholders and distract management. Variable but ongoing burn reduces runway and constrains ability to fund clinical programs or scale development without securing new financing.
Shrinking Equity And Small Asset BaseA materially reduced equity base and small asset pool limit the firm's capacity to absorb setbacks or self-fund development. This fragile balance sheet heightens fundraising risk and could force unfavorable partnership terms or accelerated dilution if clinical or regulatory progress stalls.
Nuformix Plc News
NFX FAQ
What was Nuformix Plc’s price range in the past 12 months?
Nuformix Plc lowest share price was 0.07 p and its highest was 0.56 p in the past 12 months.
What is Nuformix Plc’s market cap?
Nuformix Plc’s market cap is £4.83M.
When is Nuformix Plc’s upcoming earnings report date?
Nuformix Plc’s upcoming earnings report date is Feb 03, 2027 which is in 237 days.
How were Nuformix Plc’s earnings last quarter?
Nuformix Plc released its earnings results on May 28, 2026. The company reported 0 p earnings per share for the quarter, the consensus estimate of N/A by 0 p.
Is Nuformix Plc overvalued?
According to Wall Street analysts Nuformix Plc’s price is currently Overvalued.
Does Nuformix Plc pay dividends?
Nuformix Plc does not currently pay dividends.
What is Nuformix Plc’s EPS estimate?
Nuformix Plc’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Nuformix Plc have?
Nuformix Plc has 2,609,750,000 shares outstanding.
What happened to Nuformix Plc’s price movement after its last earnings report?
Nuformix Plc reported an EPS of 0 p in its last earnings report, expectations of N/A. Following the earnings report the stock price went down -2.941%.
Which hedge fund is a major shareholder of Nuformix Plc?
Currently, no hedge funds are holding shares in GB:NFX
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Nuformix Plc
Nuformix plc, a pharmaceutical company based in the United Kingdom, specializes in developing therapies for fibrotic diseases and cancer, primarily through the innovative strategy of drug repurposing. Its current development portfolio includes NXP001, which has advanced beyond Phase 1 trials for application in oncology supportive care. Additionally, the company is progressing NXP004, a novel variant of Olaparib, currently in its intellectual property generation stage for oncological indications, and NXP002, which is undergoing pre-clinical evaluation for the treatment of idiopathic pulmonary fibrosis. Nuformix also holds an option agreement with Oxilio Ltd. concerning NXP001 for its oncology applications. Established in 2008, the company maintains its operational base in London.
Technical Analysis
Evgen Pharma
―
Futura Medical
―
ImmuPharma
―
OptiBiotix Health
―
HemoGenyx Pharmaceuticals Plc
―